Reality Check On UK Production Capacity For COVID-19 Treatments
Debate Shifts From Treatments To Scalability, Manufacturing Capacity, And Delivery
Executive Summary
In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments.
You may also be interested in...
Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
UK 'Punching Above Its Weight' On Coronavirus Therapeutics
In the second instalment of a two-part article, members of the UK COVID-19 Therapeutics Task Force look at the various therapies currently under investigation for coronavirus patients and explain how the task force coordinates and advances the research projects being conducted under its aegis.
EU Politicians: 'Bring Pharma Manufacturing Back To Europe'
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.